Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA margin is -56.28% as of the fiscal period ended Saturday, June 30, 2018.
Reported quarterly EBITDA margin; no daily interpolation.
Limited quarterly history available
EBITDA Margin needs at least three reported quarters before a meaningful chart is shown.
EBITDA MARGIN
-56.28%
EBITDA MARGIN AVG TTM
N/A
EBITDA MARGIN AVG 3Y
N/A
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$412.30M
EBITDA Margin
-7.84%
TTM Avg
-9.54%
3Y Avg
-19.72%
5Y Avg
-25.08%
Market Cap
$411.21M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$417.06M
EBITDA Margin
-189.54%
TTM Avg
-258.01%
3Y Avg
-315.18%
5Y Avg
-540.94%
Market Cap
$406.58M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$405.74M
EBITDA Margin
39.39%
TTM Avg
8.38%
3Y Avg
8.38%
5Y Avg
8.38%
Market Cap
$418.95M
EBITDA Margin
-232.13%
TTM Avg
-495.69%
3Y Avg
-578.57%
5Y Avg
-532.48%
Market Cap
$404.24M
EBITDA Margin
-1.71%
TTM Avg
-2.46%
3Y Avg
-6.59%
5Y Avg
-11.17%
Market Cap
$419.87M
EBITDA Margin
-1867.60%
TTM Avg
-990.65%
3Y Avg
-608.01%
5Y Avg
-2572.38%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Rezolute, Inc. (RZLT) | $412.13M | -56.28% | N/A | N/A | N/A |
| Strata Critical Medical, Inc. (SRTA)vs › | $412.30M | -7.84% | -9.54% | -19.72% | -25.08% |
| MapLight Therapeutics, Inc. (MPLT)vs › | $411.21M | N/A | N/A | N/A | N/A |
| Senseonics Holdings, Inc. (SENS)vs › | $417.06M | -189.54% | -258.01% | -315.18% | -540.94% |
| Eikon Therapeutics, Inc. Common Stock (EIKN)vs › | $406.58M | N/A | N/A | N/A | N/A |
| Atea Pharmaceuticals, Inc. (AVIR)vs › | $405.74M | 39.39% | 8.38% | 8.38% | 8.38% |
| Editas Medicine, Inc. (EDIT)vs › | $418.95M | -232.13% | -495.69% | -578.57% | -532.48% |
| Myriad Genetics, Inc. (MYGN)vs › | $404.24M | -1.71% | -2.46% | -6.59% | -11.17% |
| Prothena Corporation plc (PRTA)vs › | $419.87M | -1867.60% | -990.65% | -608.01% | -2572.38% |
| Neurogene Inc. (NGNE)vs › | $402.17M | -8579.24% | -8579.24% | -8579.24% | -8579.24% |
Gross Margin
0.0%
EBITDA Margin
-56.3%
Operating Margin
0.0%
Net Margin
0.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2018-06-30 | -56.28% |
